Head Ultrasound Findings in Infants with Birth Weight >1,500 g and Gestational Age >32 Weeks Exposed to Prenatal Opioids

Abstract

Objective

This study aimed to evaluate the effects of prenatal exposure to opioids on head ultrasound (HUS) and to determine the need for routine HUS evaluation in infants exposed to prenatal opioids.

Study Design

This is a retrospective cohort study performed at a level III NICU. Infants >32 weeks gestational age and >1,500 g birth weight with prenatal opioid exposure (n = 127) were included in this study. Data including demographic information and HUS results were recorded.

Results

Twenty (16%) infants were exposed to opioids only whereas the rest of the infants (84%) were exposed to opioids plus other drugs (polysubstance) in utero. Sixteen of 127 infants (13%) had abnormal initial HUS. Sub-ependymal hemorrhage or grade 1 intraventricular hemorrhage was the most common abnormal finding. Absent septum pellucidum was seen in three infants.

Conclusion

A relatively large proportion (13%) of infants in this study had abnormal HUS findings; however, further studies are required to correlate HUS findings with a specific drug of exposure, duration of exposure, polysubstance use, umbilical cord drug concentration levels, and neurodevelopmental outcomes.

Key Points

• Limited data exists regarding HUS findings in infants with prenatal opioid exposure.

• A relatively large proportion of infants exposed to opioids in utero had abnormal HUS.

• Subependymal hemorrhages or grade I intraventricular hemorrhage was the most common abnormal finding.

Keywords

intraventricular hemorrhage - head ultrasounds - late preterm - term neonates - maternal opioid use

Publikationsverlauf

Eingereicht: 03. Dezember 2024

Angenommen: 05. März 2025

Artikel online veröffentlicht:
29. März 2025

• References

• 1 UNODC. World Drug Report 2021. United Nations Office on Drugs and Crime; 2021 . Accessed July 9, 2023. at: https://www.unodc.org/res/wdr2021/field/WDR21_Booklet_3.pdf
• 2 Opioid Facts and Statistics. National Opioid Crisis: Help and Resources. Accessed July 7, 2023 at: https://www.hhs.gov/opioids/statistics/index.html
• 3 Substance Use during Pregnancy. Centers for Disease Control and Prevention; 2023 . Accessed July 9, 2023 at: https://www.cdc.gov/reproductivehealth/maternalinfanthealth/substance-abuse/substance-abuse-during-pregnancy.htm#:~:text=Opioid%20use%20disorder%20during%20pregnancy,neonatal%20abstinence%20syndrome%20(NAS)
• 4 Weller AE, Crist RC, Reiner BC, Doyle GA, Berrettini WH. Neonatal opioid withdrawal syndrome (NOWS): a transgenerational echo of the opioid crisis. Cold Spring Harb Perspect Med 2021; 11 (03) a039669
• 5 Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol 2015; 35 (08) 650-655
• 6 Winkelman TNA, Villapiano N, Kozhimannil KB, Davis MM, Patrick SW. Incidence and costs of neonatal abstinence syndrome among infants with Medicaid: 2004-2014. Pediatrics 2018; 141 (04) e20173520
• 7 Patrick SW, Barfield WD, Poindexter BB. COMMITTEE ON FETUS AND NEWBORN, COMMITTEE ON SUBSTANCE USE AND PREVENTION. Neonatal opioid withdrawal syndrome. Pediatrics 2020; 146 (05) e2020029074
• 8 Behnke M, Smith VC. Committee on Substance Abuse, Committee on Fetus and Newborn. Prenatal substance abuse: short- and long-term effects on the exposed fetus. Pediatrics 2013; 131 (03) e1009-e1024
• 9 Richer EJ, Riedesel EL, Linam LE. Review of neonatal and infant cranial US. Radiographics 2021; 41 (07) E206-E207
• 10 Maller VV, Cohen HL. Neonatal head ultrasound: a review and update-part 1: techniques and evaluation of the premature neonate. Ultrasound Q 2019; 35 (03) 202-211
• 11 Monnelly VJ, Anblagan D, Quigley A. et al. Prenatal methadone exposure is associated with altered neonatal brain development. Neuroimage Clin 2017; 18: 9-14
• 12 Yuan Q, Rubic M, Seah J. et al; BOB (Brains, Opioids and Babies) Collaborative group. Do maternal opioids reduce neonatal regional brain volumes? A pilot study. J Perinatol 2014; 34 (12) 909-913
• 13 Merhar SL, Kline JE, Braimah A. et al. Prenatal opioid exposure is associated with smaller brain volumes in multiple regions. Pediatr Res 2021; 90 (02) 397-402
• 14 Walhovd KB, Watts R, Amlien I, Woodward LJ. Neural tract development of infants born to methadone-maintained mothers. Pediatr Neurol 2012; 47 (01) 1-6
• 15 Merhar SL, Parikh NA, Braimah A, Poindexter BB, Tkach J, Kline-Fath B. White matter injury and structural anomalies in infants with prenatal opioid exposure. AJNR Am J Neuroradiol 2019; 40 (12) 2161-2165
• 16 Kahila H, Kivitie-Kallio S, Halmesmäki E, Valanne L, Autti T. Brain magnetic resonance imaging of infants exposed prenatally to buprenorphine. Acta Radiol 2007; 48 (02) 228-231
• 17 Nagaraj UD, Kline-Fath BM, Zhang B. et al. MRI findings in third-trimester opioid-exposed fetuses, with focus on brain measurements: a prospective multicenter case-control study. AJR Am J Roentgenol 2023; 220 (03) 418-427
• 18 Radhakrishnan R, Grecco G, Stolze K. et al. Neuroimaging in infants with prenatal opioid exposure: current evidence, recent developments and targets for future research. J Neuroradiol 2021; 48 (02) 112-120
• 19 Schulson M, Liu A, Björkman T. et al. Mid-gestational enlargement of fetal thalami in women exposed to methadone during pregnancy. Front Surg 2014; 1: 28
• 20 Visconti KC, Hennessy KC, Towers CV, Howard BC. Chronic opiate use in pregnancy and newborn head circumference. Am J Perinatol 2015; 32 (01) 27-32
• 21 Towers CV, Hyatt BW, Visconti KC, Chernicky L, Chattin K, Fortner KB. Neonatal head circumference in newborns with neonatal abstinence syndrome. Pediatrics 2019; 143 (01) e20180541
• 22 Hand IL, Shellhaas RA, Milla SS. COMMITTEE ON FETUS AND NEWBORN, SECTION ON NEUROLOGY, SECTION ON RADIOLOGY. Routine neuroimaging of the preterm brain. Pediatrics 2020; 146 (05) e2020029082
• 23 Liu AR, Gano D, Li Y, Diwakar M, Courtier JL, Zapala MA. Rate of head ultrasound abnormalities at one month in very premature and extremely premature infants with normal initial screening ultrasound. Pediatr Radiol 2022; 52 (06) 1150-1157
• 24 BWH. Head ultrasound screening in premature infants. Pediatric newborn medicine clinical practice guidelines. Published 2016 . Accessed February 24, 2025 at: https://www.brighamandwomens.org/assets/BWH/pediatric-newborn-medicine/pdfs/hus-cpg.pdf
• 25 Pourcyrous M, Elabiad MT, Rana D, Gaston KP, DeBaer L, Dhanireddy R. Racial differences in opioid withdrawal syndrome among neonates with intrauterine opioid exposure. Pediatr Res 2021; 90 (02) 459-463
• 26 Rana D, McLeod AR, Gaston PK, Hill DM, Pourcyrous M. Assessing neonatal opioid withdrawal syndrome severity as a function of maternal buprenorphine dose and umbilical cord tissue concentrations. Ann Pharmacother 2023; 57 (08) 892-898
• 27 Lien J, Hayes T, Liu-Smith F, Rana D. Comparing maternal substance use and perinatal outcomes before and during the COVID-19 pandemic. J Perinatol 2023; 43 (05) 664-669
• 28 Boswinkel V, Krüse-Ruijter MF, Nijboer-Oosterveld J. et al. Incidence of brain lesions in moderate-late preterm infants assessed by cranial ultrasound and MRI: the BIMP-study. Eur J Radiol 2021; 136: 109500
• 29 Ballardini E, Tarocco A, Baldan A, Antoniazzi E, Garani G, Borgna-Pignatti C. Universal cranial ultrasound screening in preterm infants with gestational age 33-36 weeks. A retrospective analysis of 724 newborns. Pediatr Neurol 2014; 51 (06) 790-794
• 30 Bhat V, Karam M, Saslow J. et al. Utility of performing routine head ultrasounds in preterm infants with gestational age 30-34 weeks. J Matern Fetal Neonatal Med 2012; 25 (02) 116-119
• 31 Ballardini E, Tarocco A, Rosignoli C, Baldan A, Borgna-Pignatti C, Garani G. Universal head ultrasound screening in full-term neonates: a retrospective analysis of 6771 infants. Pediatr Neurol 2017; 71: 14-17
• 32 Reynolds EW, Riel-Romero RM, Bada HS. Neonatal abstinence syndrome and cerebral infarction following maternal codeine use during pregnancy. Clin Pediatr (Phila) 2007; 46 (07) 639-645
• 33 Mukerji A, Shah V, Shah PS. Periventricular/intraventricular hemorrhage and neurodevelopmental outcomes: a meta-analysis. Pediatrics 2015; 136 (06) 1132-1143
• 34 Compton WM, Valentino RJ, DuPont RL. Polysubstance use in the U.S. opioid crisis. Mol Psychiatry 2021; 26 (01) 41-50
• 35 Dogra VS, Shyken JM, Menon PA, Poblete J, Lewis D, Smeltzer JS. Neurosonographic abnormalities associated with maternal history of cocaine use in neonates of appropriate size for their gestational age. AJNR Am J Neuroradiol 1994; 15 (04) 697-702
• 36 Cohen HL, Sloves JH, Laungani S, Glass L, DeMarinis P. Neurosonographic findings in full-term infants born to maternal cocaine abusers: visualization of subependymal and periventricular cysts. J Clin Ultrasound 1994; 22 (05) 327-333
• 37 King TA, Perlman JM, Laptook AR, Rollins N, Jackson G, Little B. Neurologic manifestations of in utero cocaine exposure in near-term and term infants. Pediatrics 1995; 96 (2 Pt 1): 259-264
• 38 Bauer CR, Langer JC, Shankaran S. et al. Acute neonatal effects of cocaine exposure during pregnancy. Arch Pediatr Adolesc Med 2005; 159 (09) 824-834
• 39 National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy. In: Phillips JK, Ford MA, Bonnie RJ. et al., eds. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Washington (DC): National Academies Press (US); July 13, 2017